BMS?833923 is an orally bioavailable, potent, and selective antagonist of the HH signaling component Smoothened (SMO). BMS?833923 inhibits the expression of downstream effectors in the hedgehog pathway (GLI1 and PTCH1) in cell lines that express wild?type and activated mutant form SMO. BMS?833923 inhibited the clonogenic growth of multiple tumor cell lines derived from patients with hematological malignancies including chronic myeloid leukemia, acute lymphocytic leukemia and acute myeloid leukemia, suggesting that targeting the hedgehog pathway may have broad therapeutic utility for patients with hematologic malignancies [1]. Phase I clinical studies showed BMS-833923 is well-tolerated as a monotherapy agent or as combined agent with [2]

BMS?833923 is an orally bioavailable, potent, and selective antagonist of the HH signaling component Smoothened (SMO). BMS?833923 inhibits the expression of downstream effectors in the hedgehog pathway (GLI1 and PTCH1) in cell lines that express wild?type and activated mutant form SMO. BMS?833923 inhibited the clonogenic growth of multiple tumor cell lines derived from patients with hematological malignancies including chronic myeloid leukemia, acute lymphocytic leukemia and acute myeloid leukemia, suggesting that targeting the hedgehog pathway may have broad therapeutic utility for patients with hematologic malignancies [1]. Phase I clinical studies showed BMS-833923 is well-tolerated as a monotherapy agent or as combined agent with [2]